Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Kite Pharma’s CAR-T Clinical Trial To Use Chemotherapy Drug Implicated In Patient Deaths

XTALKS VITALS NEWS

Chemotherapy

The study is set to use both cyclophosphamide and fludarabine as preconditioning agents, though Kite says they will be administered at much lower doses than they were in the Juno trial.

Tweetables from this article:

Tweet: Kite Pharma plans to use low-dose fludarabine as a preconditioning agent  http://ctt.ec/tCdr2+Kite Pharma plans to use low-dose fludarabine as a preconditioning agent.

Tweet: Kite Pharma has already enrolled 72 patients in Phase II clinical trial http://ctt.ec/eMlN2+Kite Pharma has already enrolled 72 patients in Phase II clinical trial.

Share this!

July 15, 2016 | by Sarah Massey, M.Sc.

In its upcoming clinical trial of their CAR-T therapy, Kite Pharma plans to use low-dose fludarabine as a preconditioning agent – a drug implicated in the death of three patients in a similar study conducted by Juno Therapeutics. Following the deaths, both Juno and the US Food and Drug Administration (FDA) decided to cease using fludarabine for the remainder of the company’s clinical trial.

The FDA issued a brief clinical hold on Juno’s Phase II CAR-T study last week while the cause of the patient deaths were being investigated. Once the company had submitted the necessary information to the regulator, the ROCKET study was allowed to continue without the use of fludarabine.

Just hours after the Juno trial was stopped, Kite announced they had already enrolled 72 patients with certain blood cancers in their Phase II clinical trial of their candidate, KTE-C19. The study is set to use both cyclophosphamide and fludarabine as preconditioning agents, though Kite says they will be administered at much lower doses than they were in the Juno trial.

“Kite Pharma’s announcement regarding the enrollment of the 72nd patient marks a significant milestone in our ZUMA 1 trial,” a spokesperson for Kite Pharma told FierceBiotech. This trial is the culmination of over 10 years of study and testing where Kite and our NCI collaborators have carefully examined every aspect of CAR-T therapy including the optimal dose pre-conditioning regimen of cyclophosphamide and fludarabine and the KTE-C19 cell dose.

“Our analysis has been methodical and systematic and included dose ranging studies and a Phase I run-in to the ZUMA studies of diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL),” the spokesperson continued. “Kite’s clinical program is ongoing with data anticipated from the ZUMA 1 trial later this year.”

According to analysts at Jefferies, there have now been four patient deaths as a result of Juno’s clinical trial – a statement that has so far not been confirmed by Juno. While Juno’s shares were impacted after the trial was put on hold, they have since rebounded as the study is now allowed to continue.


Keywords: CAR-T, FDA, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.